Biotinylated Human Kallikrein 5/KLK5 Protein (active form)
Catalog No: KLK5-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human Kallikrein 5/KLK5 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ile67-Ser293 (UniProt accession: Q9Y337).
Product Details
- Molecular Aliases
- Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE
- Protein Length
- Ile67-Ser293
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 32.51 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in 50mM MES, 150mM NaCl (pH 5.5). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in 50mM MES (pH 5.5). Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human Kallikrein 5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human Kallikrein 5 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human Kallikrein 5, His-Avi tag at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-Kallikrein 5 Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA. (QC Test)
Background
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
References
- Thorpe JH, Edgar EV, Smith KJ, Lewell XQ, Rella M, White GV, Polyakova O, Nassau P, Walker AL, Holmes DS, Pearce AC, Wang Y, Liddle J, Hovnanian A. Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome. Acta Crystallogr F Struct Biol Commun. 2019 May 1;75(Pt 5):385-391. doi: 10.1107/S2053230X19003169. Epub 2019 Apr 26. PMID: 31045568; PMCID: PMC6497096.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.